Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. Issue 1 (1st February 2017)

• Record Type: Journal Article
• Authors: Bethge, Johannes; Meffert, Silvia; Ellrichmann, Mark; Conrad, Claudio; Nikolaus, Susanna; Schreiber, Stefan
• Is Part Of: BMJ open gastroenterology. Volume 4:Issue 1(2017)
• Publication Date: 2017-02-01
• Subjects: INFLAMMATORY BOWEL DISEASE -- SPONDYLOARTHROPATHY -- INTEGRINS -- TNF-ALPHA; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/bmjgast-2016-000127
• Languages: English
• ISSNs: 2054-4774

Abstract

Abstract : Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.